A Phase II Study of IMCgp100 Immunotherapy versus Standard Therapy for Metastatic Uveal Melanoma

Full Title

IMCgp100-202: A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma


Tumors are capable of inactivating immune cells called killer T cells and often evade detection by the immune system. IMCgp100 is an investigational drug that can refocus a T cell against the gp100 protein in uveal melanoma cells. In this study, researchers are comparing the safety and effectiveness of IMCgp100 with standard treatments in patients with metastatic uveal melanoma (a cancer of the eye).

Patients in this study will be randomly assigned to receive IMCgp100 or one of three standard treatments (dacarbazine chemotherapy, ipilimumab immunotherapy, or pembrolizumab immunotherapy). All of these medications are given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic uveal melanoma and may not have received any treatment for advanced disease, including liver-directed treatments such as embolization.
  • Patients must test positive for a protein in the blood called HLA-A*0201.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alexander Shoushtari at 646-888-4161.